Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany by Braun, Sebastian et al.
Original Article  · Originalarbeit
Breast Care 2009;4:389–396 Published online: December 11, 2009
DOI: 10.1159/000255840
Dipl.-Ök. Sebastian Braun
Leibniz Universität Hannover
Forschungsstelle für Gesundheitsökonomie
Königsworther Platz 1, 30167 Hannover, Germany
Tel. +49 511 762-5518, Fax -5081
sbr@ivbl.uni-hannover.de
© 2009 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/brc
Fax +49 761 4 52 07 14
Information@Karger.de
www.karger.com
BreastCare
MULTIDISCIPLINARY JOURNAL FOR RESEARCH, DIAGNOSIS AND THERAPY
Cost Effectiveness of Exemestane versus Tamoxifen  
in Post-Menopausal Women with Early Breast Cancer  
in Germany
Sebastian Brauna  Thomas Mittendorfa  Thomas Menschikb  Wolfgang Greinerc  
Johann-Matthias von der Schulenburga
a Centre for Health Economics, Leibniz University of Hanover, Germany
b European Department of Oncology, Pfizer, Paris, France
c Health Economics and Health Care Management, University of Bielefeld, Germany
Schlüsselwörter
Aromatasehemmer · Postmenopause · 
Kosteneffektivität · Brustkrebs · Frühstadium
Zusammenfassung
Hintergrund: Klinische Studien belegen, dass der Wech-
sel zu Exemestan nach 2–3 Jahren adjuvanter Tamoxi-
fentherapie die Gesamtüberlebenszeit verlängern kann. 
Bisher existieren für den deutschen Versorgungszusam-
menhang keine Studien zur Kosteneffektivität dieses 
Therapieschemas. Patienten und Methoden: Anhand 
eines Markov-Modells wird die Kosteneffektivität des 
Wechsels zu Exemestan mit der Fortführung der Tam-
oxifentherapie verglichen. Die Zielpopulation sind post-
menopausale Frauen mit Brustkrebs in Remission, die 
vor Modelleintritt 2–3 Jahre lang Tamoxifen erhalten 
haben. Die tägliche Therapie wird entweder mit 20 mg 
Tamoxifen oder mit 25 mg Exemestan für weitere 2–3 
Jahre fortgesetzt. Das Modell verwendet die Perspekti-
ve des deutschen Gesundheitswesens. Ergebnisse: Die 
inkrementellen Gesamtkosten von Exemestan betragen 
bei lebenslanger Betrachtung 4195 Euro. Die Kostenef-
fektivität liegt bei 17 632 Euro pro zusätzlichem quali-
tätsangepasstem Lebensjahr (QALY) bzw. 16 857 Euro 
pro gewonnenem Lebensjahr und 12 851 Euro für ein 
zusätzliches krankheitsfreies Jahr. Probabilistische Sen-
sitivitätsanalysen bestätigen die Stabilität dieser Ergeb-
nisse. Schlussfolgerung: Verglichen mit der verlängerten 
Tamoxifentherapie ist der Wechsel zu Exemestan nach 
2–3 Jahren kosteneffektiv in der adjuvanten Brustkrebs-
therapie bei postmenopausalen Frauen innerhalb des 
deutschen Gesundheitswesens.
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Summary
Background: Medical studies have shown that switching 
to exemestane after 2–3 years of adjuvant treatment with 
tamoxifen is effective when looking at overall survival. 
No cost effectiveness study of exemestane has been 
conducted in the German health care context. Patients 
and Methods: To assess the cost effectiveness of switch-
ing to exemestane vs. continued tamoxifen therapy for 
early-stage breast cancer, a Markov model was devel-
oped. The model population was set as postmenopausal 
women who are in remission from early-stage breast 
cancer. Upon model entry, either a continuing daily ther-
apy with 20 mg tamoxifen or a switch to 25 mg exemes-
tane for the next 2–3 years takes place. The model takes 
a German health care perspective. Results: The total in-
cremental costs of exemestane on a lifetime basis are 
4,195 Euro, resulting in an incremental cost effectiveness 
ratio of 17,632 Euro per additional quality-adjusted life year 
(QALY), or 16,857 Euro per life year gained. Incremental 
costs per disease-free year of survival are 12,851 Euro. 
Probabilistic sensitivity analyses proved the robustness 
of these findings. Conclusion: Compared to extended 
tamoxifen therapy, switching to exemestane after 2–3 
years turned out to be a cost-effective strategy in adju-
vant therapy for early-stage breast cancer in postmeno-
pausal women within the German health care context.
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Introduction
For more than 30 years, the standard approach to adjuvant 
treatment of oestrogen receptor-positive early-stage breast 
cancer in postmenopausal women was to treat patients with 
up to 5 years of tamoxifen. Tamoxifen has been shown to 
be very effective and to reduce breast cancer-related mortal-
ity by up to 50% [1]. With the third-generation aromatase 
inhibitors, an even more effective substance class was intro-
duced as therapeutic alternative [2–7]. Hence, international 
guidelines state that optimal adjuvant hormonal therapy for 
a postmenopausal woman with receptor-positive breast can-
cer should include an aromatase inhibitor, either as initial 
therapy or after treatment with tamoxifen [8]. Also German 
guidelines acknowledge the superiority of third-generation 
aromatase inhibitors compared to tamoxifen for assured 
postmenopausal woman with early-stage breast cancer [9]. 
One of the possible treatment strategies emerging from these 
guidelines and advances in daily clinical practice is to initially 
treat patients with tamoxifen for the first 2–3 years and then 
to switch to alternative treatments such as exemestane. The 
objective of this model is to assess the costs and health out-
comes of continuing to use adjuvant tamoxifen therapy for a 
further 2–3 years compared with switching to adjuvant treat-
ment with exemestane at 2–3 years, in the German health 
care context.
Patients and Methods
A Markov model was developed in Microsoft Excel® to assess the cost 
effectiveness of exemestane relative to continued tamoxifen as adjuvant 
therapy for early-stage breast cancer. Cost and health outcomes were as-
sessed in terms of the incremental cost per life year gained, the incremen-
tal cost per quality-adjusted life year (QALY) gained, or the incremental 
cost per disease-free life year gained. The latter outcome demonstrates 
the treatment impact on surrogate markers that determine whether treat-
ment is a success or a failure.
Model Structure
This model takes the perspective of the German Statutory Health Insur-
ance (SHI). It is difficult to collect data showing the productivity loss as-
sociated with early-stage breast cancer or its treatment. A true measure-
ment is likely to show that such costs are relatively small, due to the age 
of the population. The model therefore only considers health care-related 
costs.
The model uses the following health states to demonstrate differences 
between the different treatment arms in the model:
– no recurrence of breast cancer
– remission from breast cancer
– local recurrence of breast cancer
– distant recurrence of breast cancer
– contra-lateral breast cancer
– death from breast cancer
– death from other causes
Osteoporosis, endometrial cancer and thromboembolism (pulmonary 
embolism (PE) and deep-vein thrombosis (DVT)) are incorporated into 
the model as adverse events using separate health states. Osteoporosis is 
included by replicating all of the health states listed above (osteoporo-
sis with no recurrence, osteoporosis with disease remission, osteoporosis 
with local recurrence, osteoporosis with distant recurrence, osteoporosis 
with contra-lateral breast cancer). Once a patient is diagnosed with os-
teoporosis, she stays in an osteoporosis-related state but can still transi-
tion between different health states in the same way as patients without 
osteoporosis.
Endometrial cancer is incorporated in a manner different to oste-
oporosis. It is assumed that endometrial cancer ‘dominates’ other states 
in the model, so that patients can only remain in the endometrial cancer 
health state or move to death. This assumption is based on discussions 
with clinical experts. Thromboembolism is included as a reversible event 
with a separate health state. Patients are able to move to breast cancer-
related health states once the thromboembolism has resolved.
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Fig. 1. General structure of the Markov model. 
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Fig. 1. General structure of the Markov model.
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Fig. 2. Allowable transitions in the case of osteoporosis. 
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Fig. 3. Allowable transitions in the case of thromboembolism. 
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Other adverse events are also included in the model. The impacts of 
vaginal haemorrhage, cardiac failure, myocardial ischaemia, arthralgia, 
and hypertension on health care costs are incorporated into the model as 
event tolls. These events were deemed either too rare to justify a separate 
health state, or clinical advice stated that the impact on quality of life was 
likely to be minimal. The general structure of the model and its allowable 
transitions are displayed in figure 1.
Allowable transitions from two adverse events – osteoporosis and 
thromboembolism – are shown in the separate diagrams of figures 2 and 
3. Osteoporosis is a permanent condition in the model, but one that oper-
ates independently of breast cancer. That is, a patient with osteoporosis 
will have osteoporosis for the rest of her life, but the breast cancer will 
progress at the same rate as if a patient did not have osteoporosis.
Thromboembolism is also incorporated into the model. It is assumed 
that the episode is successfully treated, after which patients either remain 
in the post-thrombolytic state (equivalent to no recurrence) or transition 
to one of the other states that those in the no-recurrence health state are 
able to move to (as shown in fig. 1).
The population included in the model reflects the study data of the 
Intergroup Exemestane Study (IES) [10]. Hence, the cohort in the model 
consists of postmenopausal women with a median age of 63 years (range 
31–96 years) who had already spent an average 28.5 months (range 15.6–
Health state Utility value Source
No recurrence 0.999 Carter et al. (1998) [13]
Local recurrence 0.700 Desch et al. (1993) [14]
Remission after local recurrence 0.850 Hillner et al. (1991) [15]
Distant recurrence 0.517 Karnon et al. (2004) [16]
Contra-lateral disease 0.700 assumed as being the same as local recurrence
Osteoporosis 0.930 Kanis et al. (2005) [17]
Osteoporotic fracture 0.860 assumption – midpoint between hip (0.79) and no fracture 
(0.93); Kanis et al. (2005) [17]
Endometrial cancer 0.740 Ozanne et al. (2004) [18]
Thromboembolism 0.580 Eckman et al. (1993) [19]
Thromboembolism post treatment 0.900 Cykert et al. (2004) [20]
Death 0.000
Table 1. Health 
state and adverse 
event utilities
Probability Exemestane Tamoxifen Discontinued
From no recurrence to
Contra-lateral breast cancer 0.000536 0.001674 0.003193
Contra-lateral breast cancer (end of treatment) 0.001776 0.001776 na
Distant recurrence 0.012022 0.015596 0.016908
Distant recurrence (end of treatment) 0.011455 0.011455 na
Local recurrence 0.002765 0.004104 0.005542
Local recurrence (end of treatment) 0.002564 0.002564 na
Remaining in no recurrence residual residual residual
Death from other causes age-dependent German mortality data [11]
From disease remission to
Distant recurrence 0.051395 0.051395 na
Remaining in disease remission residual residual na
Death from other causes age-dependent German mortality data
From local recurrence to
Distant recurrence 0.051395 0.051395 na
Disease remission residual residual na
Death from other causes age-dependent German mortality data [11]
From distant recurrence to
Remaining in distant recurrence (survival) 0.179665 0.179665 na
Death from other causes age-dependent German mortality data [11]
Death from breast cancer residual residual residual
From contra-lateral breast cancer to
Distant recurrence 0.051395 0.051395 na
Remission to distant recurrence residual residual na
Death from other causes German age-specific mortality data [11]
na = Not applicable.
Table 2. Transition probabilities used in the 
first 36 months of the model
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Table 3. Cost parameters
Model parameters Costs Source
Tamoxifen 20 mg 54.31 A Red Book [25]
Exemestan 25 mg 1005.34 A Red Book [25]
Osteoporosis
Osteoporosis pharmaceuticals 210.12 A Red Book [25]
Osteoporosis fracture 2878.72 A DRG Browser V2005 [23]
Thromboembolism
Costs of the initial episode 3239.66 A DRG Browser V2005 [23]
Running costs for the first model cycle after incidence 93.28 A EBM 2000 plus [24], Red Book [25]
Following cycles up to 3 years after incidence 62.47 A EBM 2000 plus [24], Red Book [25]
Endometrial cancer
Diagnosis (once) 21.42 A EBM 2000 plus [24]
Operation (with radiotherapy) (once) 5692.97 A DRG Browser V2005 [23]
Chemotherapy (1. regime) 3201.36 A Red Book [25]
Breast cancer therapy
Operation cost (either breast ablation or preservation) (once) 4188.12 A DRG Browser V2005 [23]
Chemotherapy (1. regime responders) 3201.36 A Red Book [25]
Chemotherapy (1. regime non-responders/3 months of treatment) 1600.68 A Red Book [25]
Chemotherapy (2. regime) 11,053.95 A Red Book [25]
Terminal care
Medical home care or nursing home (14 days) 460.53 A EBM 2000 plus [24]
At hospital or hospice (14 days) 3609.53 A DRG Browser V2005 [23]
Weighted average costs 2223.97 A
63 months) on tamoxifen before either switching to exemestane or re-
maining on tamoxifen. Therefore, patients who enter the model are in re-
mission and are treated with either 20 mg tamoxifen or 25 mg exemestane 
daily. After this point, adjuvant treatment is stopped, although patients 
receive other treatments if disease progresses or if adverse events occur.
The time horizon for the cohort was lifetime (maximum 38 years from 
a starting age of 63). German age-specific mortality data [11] were used to 
incorporate death from other causes. Finally, a cycle length of 6 months 
was chosen for the model as reasonable assumption for the time taken to 
transition between the health states according to clinical experts. A half-
cycle correction was employed to take into account the fact that events 
occur during the cycle period and not only at the end of a cycle.
The model calculates the average cost and outcome on a per patient 
basis. With this, incremental cost effectiveness ratios can be calculated. 
The average costs per treatment arm over the duration of the model 
are calculated as the sum of the cycle costs on each arm. Costs and out-
comes occurring after the first year are discounted with 5% per annum, 
as recommended by the third and updated version of the Hanover Con-
sensus, which is the current guideline for health economic evaluation in 
Germany [12].
Clinical Data
The utilities attached to the different health states and adverse events 
used in the model are shown in table 1. International data had to be in-
corporated as no German-specific utilities were available for this context.
The model also includes a probabilistic sensitivity analysis. In this way, 
the impact of variation due to uncertainty around the key parameters 
(transition probabilities, costs and utilities) on the baseline cost effective-
ness results can be assessed. Probabilistic cost effectiveness results are ob-
tained using 1000 Monte Carlo simulations.
The transition probabilities used in the first 36 months of the model 
are displayed in table 2. These transition probabilities are taken from the 
results of the IES trial and represent the probability of moving from one 
health state to another. However, it is important to consider the prob-
abilities used beyond the 36-month follow-up of the pivotal trial. In order 
to be conservative, it was assumed that exemestane and tamoxifen would 
have the same effect in preventing recurrences after the end of the fol-
low-up period, despite the fact that exemestane patients showed fewer 
recurrences over the 36-month follow-up period. This is a conservative 
assumption that will increase the value of the incremental cost effective-
ness ratio.
The data used to estimate the transition probabilities after the end of 
the trial follow-up were based on three key publications. First, the prob-
abilities of progressing from no recurrence to local recurrence, distant re-
currence and contra-lateral disease were based on 15-year survival data 
for tamoxifen [1]. Firstly, this data tracks the progression of breast cancer 
patients over time and provides a strong source for estimating transition 
probabilities that are needed over the long time period. Secondly, the 
probability of remaining in the distant-recurrence health state is derived 
from a key observational study [21]. These results showed that median 
survival is 21 months among metastatic breast cancer patients, tracking 
the survival of metastatic breast cancer patients over the medium term. 
A third key source was used to estimate the probability of progressing 
from local recurrence to distant recurrence [22]. The results of that study 
showed that 41% of the patients progressed from local breast cancer 
to distant-stage breast cancer over a 5-year period. Overall, 6-month 
probabilities for each of these transitions were calculated based on these 
results.
Resource Use and Unit Costs
The model parameters were mainly identified on the basis of the DRG 
Browser [23] for inpatient costs, the EBM 2000 plus [24] (official remu-
neration within the SHI for outpatient services), and current market pric-
es for drugs [25]. With the assistance of medical experts, the appropriate 
diagnosis-related groups (DRGs) were identified. For calculation of the 
DRG-based costs, we assumed a base case value of 2831 Euro. The costs 
according to the EBM were calculated with a calculatory point score of 
0.051 Euro.
For drugs, market prices for the SHI as recorded in the Red Book 
were applied, always using the largest available package size. If a com-
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Model parameters Costs Source
Routine care if well (5 years of treatment)
Home visit by the doctor (twice per year with 20.40 A each) 204.00 A EBM 2000 plus [24]
GP visit (4 × per year with 11.48 A each) 229.50 A EBM 2000 plus [24]
Cardiac failure
GP visit 11.48 A EBM 2000 plus [24]
Cardiology outpatients 75.74 A EBM 2000 plus [24]
ECG 0.00 A EBM 2000 plus [24]
Mammogram 36.72 A EBM 2000 plus [24]
Phlebotomy 0.00 A EBM 2000 plus [24]
Biochemistry 7.20 A EBM 2000 plus [24]
Haematology 1.10 A EBM 2000 plus [24]
Spirometry 57.12 A EBM 2000 plus [24]
ECHO 0.00 A EBM 2000 plus [24]
Frusemide 25.58 A Red Book [25]
Carvedolol 217.94 A Red Book [25]
Enalapril 44.64 A Red Book [25]
Lisinopril 42.86 A Red Book [25]
Influenza vaccine 24.07 A Red Book [25]; own calculation
Pneumococcal vaccine (once) 41.97 A Red Book [25]; own calculation
Total cost of cardiac failure 421.65 A
Hypertension
GP visit 22.95 A EBM 2000 plus [24]
Bendrofluazide 2.5 mg 51.14 A Red Book [25]
Enalapril 44.64 A Red Book [25]
Lisinopril 42.86 A Red Book [25]
Atenolol 34.07 A Red Book [25]
Amlodipine 37.57 A Red Book [25]
Nifedipine XL 43.09 A Red Book [25]
Losartan 178.35 A Red Book [25]
Valsartan 77.30 A Red Book [25]
Total cost of hypertension 151.38 A Red Book [25]
Arthralgia
GP visit 11.48 A EBM 2000 plus [24]
Paracetamol 82.22 A Red Book [25]
Naproxen 56.56 A Red Book [25]
Diclofenac 26.57 A Red Book [25]
Total cost of arthralgia 66.66 A
Vaginal haemorrhage
Hysteroscopy und biopsy 683.40 A KBV EBM 2000 plus
Ultrasound 19.38 A KBV EBM 2000 plus
Histology 26.27 A KBV EBM 2000 plus
Total cost of vaginal haemorrhage 729.05 A
Myocardial ischaemia
GP visit 11.48 A EBM 2000 plus [24]
Outpatient visit cardiology 75.74 A EBM 2000 plus [24]
ECG 0.00 A EBM 2000 plus [24]
Phlebotomy 0.00 A EBM 2000 plus [24]
Biochemistry 7.20 A EBM 2000 plus [24]
Exercise tolerance test 27.80 A EBM 2000 plus [24]
GTN spray 63.72 A Red Book [25]
Atenolol 34.07 A Red Book [25]
Isosorbide mononitrate 21.40 A Red Book [25]
Total cost of myocardial ischaemia 248.40 A
ECG = Electrocardiogram, ECHO = echocardiography, GTN = glyceryl trinitrate.
Table 3. Continued
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pound was not included in the fixed-price catalogue, the price of the 
cheapest product was taken (table 3).
The costs for an osteoporosis fracture are calculated with a weighted 
average based on the real-life frequency of the relevant DRGs. A throm-
boembolism is divided into several episodes. The costs of the first episode 
are divided depending on the local occurrence of embolism in the body. In 
this context PE and DVT are relevant, which by assumption occur at 50% 
each. Costs for maintenance therapy within the first model cycle after oc-
currence include 12 general practitioner (GP) visits, 12 blood tests and a 
daily dosage of 5 mg warfarin. In the following cycles of up to 3 years, the 
number of GP visits and blood tests is reduced to 3 each and the warfarin 
medication remains stable. Costs for diagnosing an endometrium carci-
noma were assessed accordingly, with 3201 Euro making up for the first 6 
months of chemotherapy.
Inpatient costs for treating breast cancer do also result from a weighted 
DRG average adding the same costs for chemotherapy as mentioned 
above. In non-responders, the therapy stops after 3 months. Hence, for 
non-responders 6-month cycle costs are half for chemotherapy. Direct 
medical costs for 14 days of terminal care result from home care or nurs-
ing home stays (44%) and inpatient or hospice stays (56%), respectively. 
The costs for routine care are the result of 2 home visits as well as 4 GP 
outpatient visits per year.
Finally, the costs for the 5 included therapy-related adverse events 
(cardiac failure, hypertension, athralgia, vaginal haemorrhage, myocar-
dial ischaemia) were calculated as described for the other events, with 
physician services being based on the EBM and costs for drugs taken 
from the Red Book.
Results
The time spent in each health state is displayed in table 4. 
These results indicate that, over the model period, exemes-
tane patients spend 0.71 more years in a no-recurrence health 
state than tamoxifen patients (although much of this is spent 
with osteoporosis). On the other hand, tamoxifen patients 
spend more time in local and distant recurrence, remission 
following recurrence, discontinuation of treatment due to an 
adverse event, and death. As tamoxifen patients spend more 
time in health states with poorer quality of life, this is likely to 
lead to improved overall health outcomes in the exemestane 
arm. The baseline results for the incremental cost per QALY 
gained with exemestane vs. tamoxifen are shown in table 5.
The incremental cost per QALY gained with exemestane 
versus tamoxifen is 17,632 Euro, suggesting that exemestane 
Health state Time spent in each health state, years
Exemestane Tamoxifen
No recurrence 12.124 12.309
No recurrence with osteoporosis 2.243 1.343
Total time in no recurrence 14.367 13.652
Local recurrence 0.032 0.037
Local recurrence with osteoporosis 0.006 0.004
Total time in local recurrence 0.038 0.041
Contra-lateral disease 0.020 0.024
Contra-lateral disease with osteoporosis 0.004 0.002
Total time in contra-lateral disease 0.024 0.026
Distant recurrence 0.217 0.240
Distant recurrence with osteoporosis 0.039 0.025
Total time in distant recurrence 0.256 0.265
Remission 0.616 0.728
Remission with osteoporosis 0.112 0.073
Total time in remission 0.728 0.801
Endometrial cancer 0.025 0.036
Post-thromboembolism 0.152 0.355
Death 22.413 22.838
Table 4. Time spent in each health state
Exemestane Tamoxifen Incremental
Costs 10,827 A  6,631 A  4,195 A
QALY  9.9976  9.7597  0.2379
Life years 10.2656 10.0167  0.2489
Disease-free years  9.6554  9.3289  0.3265
Incremental cost per QALY 17,632 A
Incremental cost per life year gained 16,857 A
Incremental cost per disease-free 
survival year gained
12,851 A
Table 5. Base case results
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may be a cost-effective alternative adjuvant therapy in breast 
cancer. As shown by the results of the disaggregated cost and 
outcome analyses, exemestane is only slightly more expensive 
than tamoxifen over the model period, and has a clear gain in 
health outcomes. It is these two factors that drive the cost ef-
fectiveness result.
While the incremental cost per QALY gained is generally 
the key result for decision makers, it is also important to meas-
ure alternatives. Life years and disease-free years are useful 
measures of the effectiveness of cancer treatment. Hence, 
baseline results for the incremental cost per life year and per 
disease-free year gained with exemestane versus tamoxifen 
are also presented in table 5.
The cost effectiveness acceptability curve (fig. 4) comes as 
a result of the probabilistic sensitivity analysis. It represents 
the likelihood that each treatment is cost effective at vari-
ous willingness-to-pay thresholds. Hence, exemestane would 
be cost effective in over 80% of all cases at a relatively low 
threshold of 25,000 Euro per additional QALY.
Discussion
Up to now no evidence has been published regarding the cost 
effectiveness of exemestane in the German treatment setting. 
Hence, no comparison of the findings of this study with exist-
ing evidence is possible. However, internationally there exist 
three other published Markov models incorporating clinical 
data at least partly based on the results of the IES study [26–
28]. The structures of those models as well as the findings are 
quite similar to the results of this modelling approach. Each 
study looked at the cost effectiveness in specific health care 
settings (Sweden and the USA), making it difficult to transfer 
them one by one to the German health care setting. With that 
in mind, the present study gives a detailed glimpse into the 
very specific setting of the German SHI. In future regulatory 
processes, the German Institute for Quality and Efficiency in 
Health Care (IQWiG) will play a major role by not only as-
sessing benefits of novel treatment regimens but also looking 
at the cost benefit ratios. This paper could inform early dis-
cussions with such regulatory agencies in Germany, helping to 
optimise treatment not only from a clinical but also a health 
economic standpoint.
There are three main areas where our data is lacking infor-
mation or can be improved:
Firstly, the clinical data input does not completely comprise 
the findings from clinical trials. This has led to certain assump-
tions in some domains being made on the basis of expert opin-
ions. In particular, there is some missing information around 
each of the adverse events included in the model which could 
not be obtained from the literature. However, this limitation 
is quite common to a modelling approach like this and was ad-
dressed by conducting extensive sensitivity analyses reflecting 
the uncertainty around those parameters.
Secondly, there are a number of published studies that 
report utilities for health states equal or similar to those in-
cluded in the model. Those different references could be com-
bined in forming clinical data input into the model. However, 
no study could be found that included utilities for all of the 
health states used in the model. It would always be preferable 
to use as few sources as possible for the assessment of util-
ity values, as the population used to elicit utilities has a key 
role in the absolute and relative utilities. Hence, the same util-
ity values have been assigned to patients under exemestane 
and tamoxifen therapy, as there is no published information 
on differences between these two alternatives. This of course 
might be considered as being a more conservative as well as 
an optimistic reflection of treatment reality. Also, the utility 
values associated with recurrence of breast cancer were used 
as a proxy for contra-lateral breast cancer utility values, leav-
ing a chance of under- or overestimating this estimate.
Lastly, although treatment guidelines are available for 
early-stage breast cancer, they are not explicit in detailing 
which health care pathways or regimens should exactly be 
used to treat those patients. Again, this has led to assumptions 
based on expert opinions.
Conclusion
Overall, baseline results as well as results from the probabi-
listic sensitivity analysis suggest that exemestane is likely to 
be a cost-effective alternative in comparison to tamoxifen for 
adjuvant therapy of early-stage breast cancer in the German 
health care setting.
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Fig. 4. Cost effectiveness acceptability curve (cost-utility).
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